Ulrika Hamren-Wahlby

AstraZeneca R&D
Moelndal, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.

Journal: Pediatrics

Published: April 24, 2024

Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.

Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.

Journal: Nature medicine

Published: April 22, 2024

Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials.

Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials.

Journal: Pathogens (Basel, Switzerland)

Published: April 19, 2024

A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults.

A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults.

Journal: Clinical and translational science

Published: March 22, 2024

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: April 21, 2023

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.

Journal: Nature medicine

Published: September 09, 2022

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.

Journal: The Lancet. Child & adolescent health

Published: August 27, 2022

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.

Journal: The New England journal of medicine

Published: March 02, 2022

Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.

Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: August 04, 2021

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.

Journal: The European respiratory journal

Published: April 01, 2021

Longitudinal FEV1 and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling.

Longitudinal FEV1 and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling.

Journal: International journal of chronic obstructive pulmonary disease

Published: October 14, 2020

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.

Journal: Respiratory research

Published: June 12, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026